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QALYs gained, utility scores for responders and nonresponders
were derived from UK expert estimates and parent-proxy-
ratings. Incremental cost-effectiveness ratios (ICERs) were calcu-
lated including a range of scenarios for maintenance treatment
over an additional 12 months, and were subjected to multiple
sensitivity analyses. RESULTS: Eight-week remission rates were
4% (MPH b.i.d.), 23% (MPH-IR t.i.d.), and 47% (MPH-
OROS). For cost per response achieved, ICERs were €388 for
MPH-OROS versus MPH-IR t.i.d. and €206 versus MPH-IR
b.i.d.; ICERs for maintenance of response over 14 (2 + 12)
months were €2,773 for MPH-OROS versus MPH-IR t.i.d. and
€2,224 versus MPH-IR b.i.d., assuming that nonresponders dis-
continue drug treatment. Cost-per-QALY-gained for MPH-
OROS versus MPH-IR t.i.d. was between €16,500 and €44,000,
or €11,200 to €26,200 after adjustment for the Finnish 42%
medication refund policy. Across all sensitivity analyses, MPH-
OROS showed extended dominance over MPH-IR t.i.d. when
compared to a Do Nothing scenario. CONCLUSIONS: By
current standards, ICERs for MPH-OROS appear to fall well
within the limits considered acceptable, especially considering
the limited scope of the analysis (patient symptom improvement
only, without taking into account long-term sequelae or impact
on caregivers).
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OBJECTIVES: Coexisting mental health disorders are common
in patients with ADHD and may increase utilization of health
care services and therefore expenditures. The present study was
designed to address the impact of comorbidities on the direct
medical costs incurred by statutory health insurance (SHI) for
patients with and without ADHD. METHODS: For a retrospec-
tive matched cohort study, concomitant diagnoses and health
care resource utilization data for patients age 7 to 19 years with
a diagnosis of ADHD (F90.0 and/or F90.1) and for a randomly
selected control group (matched 1:1 by age and gender) were
extracted from the Nordbaden claims database (for year 2003),
and were combined with SHI prescription data. Complete
datasets were available for 2171 children age 7–12 years and 768
adolescents age 13–19 years with a diagnosis of ADHD, plus the
same number of control persons. For costing, resource use was
valued applying SHI acquisition costs. Patient subgroups were
deﬁned by the (additional) presence of the most prevalent comor-
bidities, i.e., conduct and personality disorders, mood and affec-
tive disorders, speciﬁc development disorders, and adjustment
disorder. RESULTS: Average costs per patient with ADHD were
€622/€661 (children/adolescents) compared to €245/€250 for
controls. ADHD with coexisting conditions caused the following
direct medical expenditures: in the additional presence of
conduct and personality disorder, €703/€769; mood and affective
disorders, €714/€761; speciﬁc development disorders, €630/
€766; adjustment disorder, €829/€963. Average costs for patients
with these disorders but without ADHD were also increased, and
will be reported in detail. CONCLUSIONS: The present data are
limited since they do neither include costs of inpatient treatment
nor cost of ergotherapeutic interventions, which will have to be
addressed in future studies. They provide nevertheless, for the
ﬁrst time, insight into the impact of coexisting conditions on the
ﬁnancial burden for the SHI associated with a diagnosis of
ADHD.
PODIUM SESSION I: QUALITY OF LIFE/PREFERENCE-
BASED MEASURES I: ISSUES WITH INSTRUMENTS
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OBJECTIVE: The increasing inclusion of Patient Reported
Outcome (PRO) measures in large multi-country trials has intro-
duced many new methodological challenges. PROs are often
developed in English and translated into the various languages
needed to support these global trials. Data is often pooled and
there are concerns about the process, but currently no established
criteria, to assure the appropriateness of the aggregation of data
derived from multiple languages and cultures. METHODS: A
literature review was conducted in order to investigate what
methods have been used to assess measurement equivalence
across translated PROs. Discussions were held between members
of the task force and comments were sought from the ISPOR
membership. RESULTS: A diverse range of methods have been
employed to assess measurement equivalence across translated
PROs. These include: classical test theory, factor analysis, struc-
tural equation modelling (SEM), and Differential Item Function-
ing (DIF). Basic measurement characteristics such as means,
standard deviations etc have been evaluated when the samples
are large enough, or basic measurement properties (distribution,
internal consistency etc) have been veriﬁed in a at least a few
languages. If measurement equivalence is lacking it is suggested
that qualitative research, analysis of existing trial datasets,
and/or consultation with in-country health professionals could
be carried out to investigate possible reasons for the lack of
equivalence. CONCLUSION: While data pooling across
languages/cultures is common practice, there is no clear recom-
mendation about methods or the level of measurement equiva-
lence required to determine whether pooling is appropriate or
not. There is a need for practical steps to be taken in order to
investigate and resolve lack of measurement equivalence and a
great need for further research in this area.
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OBJECTIVES: To help clinicians determine the presence of sui-
cidality, the C-SSRS was developed in US English and contains
suggested probes to assess suicidal ideation and behaviour, their
severity, and lethality of suicidal attempts. Prior to use in an
international study to investigate suicidality, the clinician rated
C-SSRS had to be translated into 45 languages for 33 countries. A
rigorous methodology was required to ensure conceptual equiva-
lence and cultural relevance across languages. METHODS: The
process was conducted by specialists in each target country,
following a standardized methodology: 1) two forward transla-
tions by native target language speakers; 2) comparison and
reconciliation of the translations; 3) back translation by a native
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